Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses
Tremlett, H and van der Mei, IAF and Pittas, F and Blizzard, CL and Paley, G and Dwyer, T and Taylor, BV and Ponsonby, AL (2008) Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety, 17 (6). pp. 565-576. ISSN 1053-8569
|PDF - Full text restricted - Requires a PDF viewer|
Official URL: http://dx.doi.org/10.1002/pds.1593
Background Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS). However,
predictors of adherence are not well understood; past studies lacked lifestyle factors such as alcohol use and predictors of
missed doses have not been evaluated. We examined both levels of non-adherence—stopping IMD and missing doses.
Methods This longitudinal prospective study followed a population-based cohort (n=199) of definite MS patients in
Southern Tasmania (January 2002 to April 2005, source population 226 559) every 6 months. Baseline factors (demographic,
clinical, psychological and cognitive) affecting adherence were examined by logistic regression and a longitudinal analysis
(generalized estimating equation (GEE)).
Results Of the 97 patients taking an IMD (mean follow-up=2.4 years), 73% (71/97) missed doses, with 1 in 10
missing>10 doses in any 6-month period. Missed doses were positively associated with alcohol amount consumed per
session ( p=0.008). A history of missed doses predicted future missed doses ( p<0.0005). Over one-quarter (27/97) stopped their current IMD, which was associated with lower education levels ( p=0.032) and previous relapses ( p=0.05). No
cognitive or psychological test predicted adherence.
Conclusions There were few strong predictors of missed doses, although people with MS consuming more alcoholic drinks
per session are at a higher risk of missing doses. Divergent factors influenced the two levels of non-adherence indicating
the need for a multifaceted approach to improving IMD adherence. In addition, missed doses should be assessed
and incorporated into clinical trial design and clinical practice as poor adherers could impact on clinical outcomes.
|Additional Information:||The definitive published version is available online at: http://interscience.wiley.com|
|Keywords:||multiple sclerosis; adherence; compliance; immunomodulatory treatment; beta-interferon; glatiramer
|Deposited By:||Ms Emma Stubbs|
|Deposited On:||10 Dec 2008 09:23|
|Last Modified:||04 Mar 2009 10:35|
|ePrint Statistics:||View statistics for this ePrint|
Repository Staff Only: item control page